Wealth Enhancement Advisory Services LLC Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Wealth Enhancement Advisory Services LLC grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 183.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,525 shares of the biopharmaceutical company’s stock after purchasing an additional 9,407 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Alnylam Pharmaceuticals were worth $6,675,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of ALNY. Salomon & Ludwin LLC purchased a new stake in Alnylam Pharmaceuticals in the third quarter worth about $27,000. ORG Partners LLC raised its position in shares of Alnylam Pharmaceuticals by 70.2% in the 3rd quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 33 shares in the last quarter. Quent Capital LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $39,000. Hilltop National Bank bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $41,000. Finally, Atlantic Union Bankshares Corp purchased a new stake in Alnylam Pharmaceuticals in the second quarter worth $30,000. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Stock Down 3.2%

NASDAQ:ALNY opened at $357.98 on Monday. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. The firm has a market cap of $47.29 billion, a P/E ratio of 1,491.58 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The firm has a 50-day simple moving average of $409.91 and a two-hundred day simple moving average of $423.98.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Barclays raised their price objective on Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Wells Fargo & Company decreased their price target on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a research note on Tuesday, January 20th. Raymond James Financial reissued an “outperform” rating and set a $472.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, January 12th. Truist Financial cut their price objective on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Finally, Bank of America decreased their target price on shares of Alnylam Pharmaceuticals from $530.00 to $529.00 and set a “buy” rating for the company in a research note on Monday, January 12th. Twenty-two equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $485.21.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,650 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $453.69, for a total transaction of $7,100,248.50. Following the sale, the chief executive officer directly owned 65,409 shares in the company, valued at approximately $29,675,409.21. This trade represents a 19.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 12,128 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, November 17th. The stock was sold at an average price of $452.18, for a total value of $5,484,039.04. Following the completion of the sale, the executive vice president directly owned 21,264 shares of the company’s stock, valued at approximately $9,615,155.52. The trade was a 36.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 56,955 shares of company stock worth $24,072,733 in the last three months. Corporate insiders own 1.20% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.